Ninety-three percent of pediatric patients (55 of 59) with relapsed/refractory acute lymphoblastic leukemia (ALL) went into remission after receiving an investigational therapy made from their own immune cells, with continuous remissions of over one year in 18 patients and over two years in nine patients. In an emerging new use of the same therapy, known as CTL019, more than half of patients (15 of 28) with non-Hodgkin lymphoma (NHL) also responded to infusions of the personalized cellular therapy.

Findings from these two clinical trials, conducted by researchers from the Perelman School of Medicine at the University of Pennsylvania and The Children’s Hospital of Philadelphia, will be presented during the 57th Annual Meeting of the American Society of Hematology (ASH).
Read the Department of Communications news release.